Tadalafil Reduces Myeloid-Derived Suppressor Cells and Regulatory T Cells and Promotes Tumor Immunity in Patients with Head and Neck Squamous Cell Carcinoma

Donald T. Weed1, Jennifer L. Vella2, Isildinha M. Reis3, Adriana C. De la fuente2, Carmen Gomez4, Zoukaa Sargi1, Ronen Nazarian1, Joseph Califano5,6, Ivan Borrello7, and Paolo Serafini2

Abstract

Purpose: Myeloid-derived suppressor cells (MDSC) and regulatory T cells (Treg) play a key role in the progression of head and neck squamous cell carcinoma (HNSCC). On the basis of our preclinical data demonstrating that phosphodiesterase-5 (PDE5) inhibition can modulate these cell populations, we evaluated whether the PDE5 inhibitor tadalafil can revert tumor-induced immunosuppression and promote tumor immunity in patients with HNSCC.

Experimental Design: First, we functionally and phenotypically characterized MDSCs in HNSCCs and determined, retrospectively, whether their presence at the tumor site correlates with recurrence. Then, we performed a prospective single-center, double-blinded, randomized, three-arm study in which patients with HNSCC undergoing definitive surgical resection of oral and oropharyngeal tumors were treated with tadalafil 10 mg/day, 20 mg/day, or placebo for at least 20 days preoperatively. Blood and tumor MDSC and Treg presence and CD8+ T-cell reactivity to tumor antigens were evaluated before and after treatment.

Results: MDSCs were characterized in HNSCC and their intratumoral presence significantly correlates with recurrence. Tadalafil treatment was well tolerated and significantly reduced both MDSCs and Treg concentrations in the blood and in the tumor (P < 0.05). In addition, the concentration of blood CD8+ T cells reactive to autologous tumor antigens significantly increased after treatment (P < 0.02). Tadalafil immunomodulatory activity was maximized at an intermediate dose but not at higher doses. Mechanistic analysis suggests a possible off-target effect on PDE11 at high dosages that, by increasing intracellular cAMP, may negatively affect antitumor immunity.

Conclusions: Tadalafil seems to beneficially modulate the tumor micro- and macro-environment in patients with HNSCC by lowering MDSCs and Tregs and increasing tumor-specific CD8+ T cells in a dose-dependent fashion. Clin Cancer Res; 21(1); 39–48. ©2014 AACR.

Introduction

Head and neck squamous cell carcinoma (HNSCC) is a deadly disease with significant social and economic impact. Despite advances in multimodality treatment and improvements in mortality rates, loco-regional recurrence rates remain high. Although many factors contribute to treatment failure in HNSCC, some of the most important are the profound immune defects found in these patients. Such defects include generalized T-cell anergy and increased concentration of myeloid-derived suppressor cells (MDSC) and regulatory T cells (Treg).

Since the mid-1990s, it has been known that MDSC (at that time called natural suppressors cells; ref. 3) recruitment at the tumor site is a negative prognostic factor and is associated with an increased rate of metastasis and recurrence in HNSCC. Furthermore, the increased frequency of CD34+ MDSC in the peripheral blood mononuclear cells (PBMC) of patients with HNSCC has also been correlated with suppression of amnestic responses to recall antigens. Human MDSCs were later described as CD34+CD33+CD11b+HLADR immature cells. More recently two additional CD33-CD11b+MDSC subsets have been included: the CD15+CD14- granulocytic-MDSCs (g-MDSC) and the CD14+CD15+ monocytc MDSC (m-MDSC; refs. 7–11). Both...
Translational Relevance

The immune system of patients with head and neck squamous cell carcinoma (HNSCC) is suppressed by the accumulation of myeloid-derived suppressor cells (MDSC) and regulatory T cells (Treg) whose presence in many malignancies has been associated with a poor prognosis. Preclinical models have shown that the immunosuppressive action of MDSCs and Treg can be overcome by the use of phosphodiesterase-5 (PDE5) inhibitors. Here, for the first time, we demonstrate by a double-blinded, placebo-controlled clinical trial in patients with HNSCC that these preclinical findings hold true in humans. Specifically, a short course of daily tadalafil treatment is sufficient to significantly (i) reduce MDSCs and Treg systemically and at the tumor site, (ii) increase the percentage of tumor-specific CD8+ T cells in circulation, and (iii) promote the activation of CD8+ T cells at the tumor site. This study provides the rationale for new therapeutic strategies in human malignancies.

Prospective study

Patients with a biopsy-proven SCC of the oral cavity or oropharynx undergoing curative surgical resection of the tumor were eligible. Patient characteristics are described in Supplementary Table S2. Enrolled patients were randomized in a ratio of 3:3:1 to arm A (10-mg tadalafil), arm B (20-mg tadalafil), or arm C (placebo), using a permuted block design with block size 7 (six blocks). Patient recruitment procedures, randomization, inclusion and exclusion criteria, and the statistical considerations in trial design are detailed in the Supplementary Data.

Specimen collection

Blood (30 mL) was drawn before treatment (t1) and at the day of the surgery (after treatment, t2) in EDTA-containing tubes. At least 6 weeks after surgery (t3), blood (60 mL) was drawn for dendritic cell (DC) preparation and additional analyses. White blood cells were purified from the blood using Ficoll-Hypaque, recovering both the lymphocytes interphase and most of the neutrophil-containing Ficoll phase but discarding the RBC pellet. Fresh tumor specimen (at least 14 mm3) was collected at t2 for tumor lysate preparation and was processed within 1 hour of harvesting. Additional specimens from the pretreatment biopsy and surgery were paraffin-embedded for immunofluorescence studies.

Interim monitoring

An adverse event (AE) questionnaire was administered to each patient on day 5 of treatment with study drug. Criteria for discontinuation of therapy were defined and are included in the Supplementary Data for both efficacy and toxicity. No dose modifications were allowed. The study was reviewed quarterly by the Data Safety and Monitoring Committee of the University of Miami Sylvester Comprehensive Cancer Center (Miami, FL). Stopping guidelines were defined for grade 2 or higher treatment-related episodes of toxicities associated with tadalafil use (headache, dyspepsia, back pain, myalgia, nasal congestion, flushing, and limb pain). Development of more significant toxicities of priapism, visual symptoms, or hearing loss in 2 patients on a single treatment arm would result in the stopping of that arm.

Flow cytometry

Flow cytometry was performed on cryoconserved follicled specimens. The used of cryoconserved specimen was initially chosen to minimize inter-assay variation, and to allow for inclusion of additional antibodies in the analysis if new MDSC-specific markers were discovered during the trial. Data acquisition was performed at the SCCC flow cytometry core on a BD LSR-Fortessa SORP equipped with the following wavelengths lasers: 355 nm (60 mW), 404 nm (100 mW), 488 nm (50mW), 561 nm (50 mW), and 639 nm (40 mW). MDSC phenotype analysis was performed using LIVE/DEAD Fixable Yellow Dead Cell (Invitrogen) and the following anti-human Abs: CD13-APC (clone Wm15; BD), CD15-PercP (clone Wd63; BioLegend), CD33-APC (clone WM53; BD), CD34+PE-Cy7 (clone 8G12; BD), HLA-DR bright violet 711 (clone L243; BioLegend), CD14-APC-H7 (clone MepP9; BD), CD11b-Pacific Blue (clone ICRF44; BD). DC analysis was performed using LIVE/DEAD Fixable Yellow Dead Cell (Invitrogen) with the following antibodies: CD11c-APC (clone B-ly6; BD), CD80-PE (clone I307.4; BD), CD86-FITC (clone 2331; BD), CD40-V450 (clone 5C3), IL4Rα-PE (clone

Patients and Methods

Retrospective study

Paraffin-embedded tumor specimens from patients with human papillomavirus (HPV)-negative oral SCC (OSCC) T1 or T2 who underwent surgical resection without prior treatment were evaluated (same specimens used in ref 20). Patient characteristics are described in Supplementary Table S1. Forty-nine patients were classified as cases or controls based on whether or not medical records included evidence of disease recurrence within 36 months after surgery (allowing a 2.5-month buffer). This resulted in 19 cases of recurrence at a median time of 12.3 months (range, 3.7–38.5) and 30 nonrecurrent controls with a median follow-up of 59.7 months (range, 36.9–103).
Tadalafil Beneficially Modulates the Immune System in HNSCC

25463; R&D Systems). T-cell analysis was performed using LIVE/DEAD Fixable Yellow Dead Cell (Invitrogen) with the following antibodies: CD3-perc (clone SP34-2; BD), CD8-PE-Cy7 (clone RPA-T8), CD4-Paci (clone RPA-T4; BD), CD25-PE (clone M-A251; BD), CD69-APC-Cy7 (clone FN50; BD), Foxp3-APC (clone PCH101; e-Bioscience). Proliferation was evaluated using CD3-perc (clone SP34-2; BD), CD8-PE-Cy7 (clone RPA-T8), CD4-Alexa Fluor 700 (clone RPA-T4; BD), CFSE (Invitrogen), and DAPI as vital dye staining. Staining was performed by 5 × 10^5 fiocillated PBMCs, blocked for 10 minutes with fc blocking peptide (Innovex Bioscience) at 4°C, stained with the optimized concentration of surface antibodies in 100 μL of PBS-BSA-EDTA (1 × 0.5%-2 nmol/L) for 15 minutes at 4°C with washed with PBS. LIVE/DEAD staining and eventual permeabilization and fixation were performed according to the manufacturer's instructions. Foxp3 staining was performed using IC Fixation Buffer and Permeabilization Buffer (e-Bioscience) following the manufacturer's instructions. Samples were read in the cytometer within 3 hours of staining. At least 10^5 events were collected. Compensations were performed using compi-beads (BD) after data collection. FMOs were used as negative controls. Data were analyzed using the FCS v3 (denovo software). Gating strategy for MDSCs quantification is summarized in Supplementary Fig. S1. For Treg quantification, the percentage of CD3^+CD4^+CD25^+Foxp3^+ T cells among "Live" cells was evaluated. The CD4:CD8 ratio was evaluated among the CD3^+ Live T cells.

**FACS sorting**

For the suppressive assay, cyoreconserved PBMCs were thawed and stained with Perpc-Cy5.5-conjugated anti-human HLADR, FITC-conjugated anti-human CD33 (BD) and PE-conjugated anti-human IL4Rε (R&D Systems). For the cGMP and cAMP analysis, cyoreconserved PBMCs from patients treated with "high" or "intermediate" dose of tadalafil, cells were labeled with: BV421-conjugated anti-human CD3 (e-Bioscience), FITC-conjugated anti-human CD33 (BD), PE-conjugated anti-human IL4Rε (R&D Systems), and brilliant violet 711-conjugated anti-human HLADR. Cells were sorted at the Diabetes Research Institute (DRI) flow cytometry core at the University of Miami, Miami, FL, using a BD-FACS-Aria.

**Suppressive assays**

Ficol-purified, FACS-sorted, CD33^+IL4Rε^+ HLADR^-, CD33^+IL4Rε^-HLADR^+ or CD33^+IL4Rε^- cells were isolated by FACS from HNSCC patients' ficol-purified PBMCs. Cells (5 × 10^5) of each cell type were then incubated with 10^5 CFSE-labeled, magnetically purified CD3^+ T cells stimulated with 7.5 × 10^5 anti CD3/anti-CD8-conjugated beads (Life Technologies). CD3^+ CD8^- T-cell proliferation was evaluated by FACS 3 days later.

**Dendritic cells preparation**

Monocytes from freshly drawn PBMCs were isolated by adherence in a T75 flask (BD) for 2 hours in RPMI-1640 containing 1% heat-inactivated human AB serum. Following washing to remove nonadherent cells, the adherent monocytes were differentiated into DC with RPMI-1640 1% AB serum containing 800 U/mL GM-CSF and 500 U/mL IL4 (Peprotech) for 5 days. Fresh GM-CSF and IL4 was added on day 3. On day 5, immature DC were transferred into 24-well plates and pulsed with autologous tumor lysate (50 μg/mL) in RPMI-1640 1% AB serum supplemented with GM-CSF and IL4. Two hours later, puls cultured immature DC were induce to mature by the addition of Mimic cytokine mix [5 ng/mL TNFa (Peprotech), 5 ng/mL IL-1β (Peprotech), 750 ng/mL IL-6 (Peprotech), and 1 μg/mL PGE2 (Sigma)].

**Tumor lysate preparation**

Fresh tumor specimens were processed within 1 hour of resection, washed twice with PBS, and incubated for 20 minutes at 37°C with five volumes of PBS containing Clostridium histolyticum collagenase type IV (10 mg/mL Sigma), MgCl2 (100 μmol/L), and CaCl2 (100 μmol/L). Cells were filtered, washed with PBS, and frozen in RPMI at −80°C until the day in which DC needed to be pulsed. Before use, cells were lysed by three additional snap-freeze (dry-ice + ethanol) and thaw (37°C cycle), and cellular debris removed by cell centrifugation and filtration through a 0.4-μm filter. Protein concentration was quantified by the BCA Protein Assay Kit (Thermo Scientific).

**Magnetic sorting**

CD3^- T cells were purified by negative selection using the human Pan T Cell Isolation Kit II (Miltenyi Biotec) in combination with the LS column and following the manufacturer's instructions. Purity was evaluated by FACS and was generally higher than 90%.

**Functional assays**

Magnetically purified, CFSE-labeled T cells (10^6) from T1, T2, or T3 were incubated with 3 × 10^5 autologous, monocyte-derived, DC pulsed with the autologous tumor. CD3^-CD8^- T-cell proliferation was evaluated by FACS 4 days later.

**Immunofluorescence staining and analysis**

Quantification of the tumor leukocyte infiltration was performed by standard techniques (Supplementary Data) and analyzed using the previously described computer-aided method (20).

**cGMP and cAMP evaluation**

cGMP and cAMP concentration was measured on the acetylated lysate of sorted cells (at least 4 × 10^5) by competitive ELISA (Enzo Life Science) following the manufacturer’s instructions. Results were normalized by the number of sorted cells used in each assay.

**Statistical analysis**

The study was designed to enroll at least 42 patients with an estimated postenrollment exclusion rate of 20% and was designed to analyze most data using paired tests to minimize the influence of inter-individual variation. The analysis of intratumoral responses was performed by one-side ANOVA at \( t_2 \), because preoperative biopsy tissues were generally too small for sufficient sampling. Time comparison within a treatment arm was assessed by one-sample \( t \) test or the Wilcoxon signed-rank test. Comparisons between treatment arms were done by two-sample \( t \) tests or ANOVA, or by nonparametric methods, the Mann–Whitney or Kruskal–Wallis test. All tests were two-sided with 5% significance. Statistical considerations on study design are detailed in the Supplementary Data.

**Results**

**Clinical trial design and protocol adherence**

We performed a single-center, double-blinded, randomized, three-arm study (Clinicaltrials.gov: NCT00843635) in which
patients undergoing definitive surgical resection of oral and oropharyngeal HNSCC were treated with tadalafil 10 mg/day, 20mg/day, or placebo (3:3:1 ratio) for at least 20 days preoperatively. Study drug was discontinued approximately 36 hours before surgery, and not given postoperatively. Exclusion and inclusion criteria and enrollment procedures are detailed in the Supplementary Data. Tadalafil was studied as an investigational new drug for a non-FDA-approved indication (IND102495; D.T. Weed, IND holder and sponsor). All subjects received appropriate standard of care adjuvant therapy postoperatively. The primary endpoints of the trial were: (i) to determine the effect of PDE5 inhibition on MDSC and Treg, (ii) to evaluate the effect of PDE5 inhibition on tumor T-cell immunity, and (iii) to evaluate whether dose response was present.

Forty-seven patients consented and enrolled in the trial. Twelve were subsequently found to have exclusion criteria or voluntarily withdrew. Of the 35 patients who were randomized and started on study drug, one was subsequently found to be taking an exclusionary medication and was withdrawn from the study after 2 days of treatment. Three patients voluntarily withdrew from the study after experiencing grade 3 side effects (back pain and myalgia; see below). Of the 31 patients who completed therapy, 29 took 20 doses of study drug; 1 patient took only 18 doses due to inadvertent noncompliance with study protocol but did take last dose 2 days before surgery; and 1 patient took a total of 32 doses of study drug due to a delay in the surgical date that occurred after initiation of study drug.

Patients’ characteristics and drug toxicity

Of the 35 patients who were randomized, the mean age was 60 years with 27 males (77%) and 8 females (23%; Supplementary Table S2). The majority of randomized patients had oral cavity tumors (31, 88.6%); 4 patients (11.4%) had oropharyngeal tumors. Twenty-six patients (74.3%) were previously untreated, 4 (11.4%) received prior chemotherapy and radiotherapy, and 5 (14.3%) received prior radiotherapy. Five patients had HPV-positive tumors. All three treatment groups had similar distributions of age, sex, site, and T stage. Although differences were not statistically significant at $P = 0.05$, the 10-mg tadalafil group had a higher percentage of white non-Hispanics, the 20-mg tadalafil group had a higher percentage of previously untreated patients, and the control group had a higher percentage of N0 tumors. Patient demographics are detailed in Supplementary Table S2.

Among the 35 patients who received study drug, no patient experienced priapism, visual changes, or hearing loss (the most serious rare side effects of tadalafil). A total of four serious AEs (SAE) occurred, all determined to be unrelated to the study drug. A total of 102 AEs (Supplementary Table S3) occurred with 1 AE noted at baseline. Seven grade 3 AEs were noted, four of which were unrelated to study drug and did not interfere with study drug completion. Three grade 3 AEs were felt to be related to study drug and resulted in voluntary withdrawal from the study. The 3 patients that withdrew from the study experienced severe back pain or myalgia following administration of 2, 3, and 3 doses of study drug respectively. All had complete resolution of symptoms within 24 hours of discontinuation of study medication (Fig. 1). Interestingly, grades 2 and 3 AEs were associated with tadalafil arms, whereas grade 1 AEs were distributed equally between placebo and tadalafil groups. Most grades 2 and 3 AEs were related to skeletal muscular pain (Supplementary Table S3).

Blinded interim analyses were performed after accrual of the first 15 evaluable patients, with no stopping criteria met for minimal immunologic effect in the active treatment arms (as identified by the 3:3:1 randomization ratio). No stopping criteria were met for adverse effects as determined by blinded quarterly review of AEs by the data safety and monitoring committee of the Sylvester Comprehensive Cancer Center.

MDSCs in HNSCC can be defined as CD33$^+$ IL4R$^+$ CD14$^+$ HLADR$^{neg/int}$ CD11b$^+$ cells

Because a consensus on human MDSC phenotype has not yet been reached (23), we first defined functionally the MDSC phenotype in HNSCC. MDSCs were sorted from PBMCs based on the expression of the pan-myeloid marker CD33, the MDSC functional marker IL4R (24–26), and HLADR. Suppressive activity of the sorted cells was assessed against autologous, anti-CD3/anti-CD28 stimulated, CFSE$^+$ T cells. Although no suppression was observed using CD33$^+$ IL4R$^+$ cells (Fig. 2A), a significant suppressive activity was observed with the CD33$^+$ IL4R$^+$ cells regardless of their HLADR expression. This population (Fig. 2B, blue dots) has a phenotype consistent with the...
The prognostic value of CD33+IL4Rα+ cells presence was evaluated through a case–control retrospective analysis of 49 patients with T1–T2 oral SCC. In particular, intratumoral concentration of CD33+IL4Rα+ MDSC was compared in 19 patients whose tumor recurred within 36 months form surgery, and 30 recurrence-free patients. This analysis (Fig. 2C) reveals that CD33+IL4Rα+ MDSCs not only suppress T-cell proliferation, but that their intratumoral accumulation correlates with tumor recurrence. This correlation is still significant in multivariate analysis with adjustment for clinical predictors (Supplementary Table S4).

Daily tadalafl treatment alters the tumor macroenvironment by reducing MDSCs and Treg in HNSCC patients

Once the MDSC phenotype was defined, the effect of preoperative tadalafl treatment was evaluated. In particular, m-MDSC and Treg concentration was evaluated in PBMCs harvested before treatment (t1), at the time of the surgery (t2), and at least 6 weeks after surgery (t3). Contrary to the placebo group (median decrease of 1.23% from baseline), a significant decrease of both m-MDSC and Treg was observed in most of the tadalafl-treated patients (Fig. 3). Discrepancies were observed at t3 among patients with some that maintained low levels of MDSC and Treg while others demonstrated an increase in either or both populations. No experimental drug was administered between t2 and t3.

Daily tadalafl treatment increase antitumor immunity

To evaluate whether PDE5 inhibition could increase antitumor immunity, magnetically purified CD3+ T cells, harvested before and after tadalafl treatment and 6 weeks after surgery, were stimulated with autologous DCs pulsed with the autologous tumor lysate. CD8+ T-cell proliferation was evaluated 4 days later by FACS. A significant increase of CD8+ T-cell proliferation was observed in both tadalafl arms, while no differences were observed in the placebo group (Fig. 4).

Tadalafl dosing and immune modulation

Neither tadalafl dose category (10 vs. 20mg) demonstrated clear superiority with regard to modulation of immunologic parameters (Figs. 3 and 4). Because tadalafl blood concentration negatively correlates with plasma volume that is directly dependent on body weight (27, 28), we evaluated whether a dose response was present once the dose was normalized on the body weight. Although it is important to emphasize that the trial was not designed to test the efficacy of a mg/kg dosing strategy, this analysis nevertheless yielded the surprising result that the decrease of MDSC and the increase of CD8+ proliferation in response to tumor antigen following tadalafl treatment was described better by a quadratic curve than by a linear regression (Fig. 5A and B). This analysis suggests that tadalafl’s maximal immunomodulatory effect is achievable between a dose of 145 and 225 μg/kg, while at higher doses, the immunomodulatory effect is significantly attenuated. Similar results were obtained when dose was normalized by body surface area, plasma volume, or body mass index (BMI; Supplementary Fig. S2). Of note, no statistically significant differences in patients’ BMI were present between study arms or dose/kg groups (data not shown).

In addition to its inhibitory effects on PDE5, tadalafl can also inhibit PDE11 (29–31). Although PDE5 degrades cGMP...
Figure 3. Tadalafil reduces MDSCs and Treg. MDSCs (A) and Treg (B) concentration was evaluated in patients PBMCs before (t1), after tadalafil treatment (t2), and 6 weeks after surgery (t3). Pw, Wilcoxon signed-rank test; Pb, paired t test.

Figure 4. Tadalafil increases antitumor immunity. T cells from PBMCs drawn at t1, t2, or t3 were stimulated with monocytes-derived autologous DC pulsed with autologous tumor. Four days later, CD8+ T-cell proliferation was evaluated by FACS. Background from parallel culture using unpulsed DC was subtracted. Pw, Wilcoxon signed-rank test; Pb, paired t test.

Weed et al.

exclusively, PDE11 can hydrolyze both cAMP and cGMP (30). On the basis of the immune-inhibitory role of cAMP (32–35) and on PDE11 expression on monocytes and T cells, we hypothesized that the dose/kg efficacy findings could be explained by the off-target PDE11 inhibition. To test this hypothesis, we measured the concentration of cGMP and cAMP in CD3+ T cells, CD33+

HLADRhigh antigen-presenting cells, and CD3+CD33+IL4Rα+ MDSC isolated from the PBMCs of patients treated with either high dose (>225 μg/kg) or intermediate dose (145 μg/kg < tadalafil < 225 μg/kg) of tadalafil (Fig. 5C and D). Although at high doses, both cGMP and cAMP are significantly increased by tadalafil treatment, at intermediate doses only cGMP is increased. These data suggest that at high tadalafil doses, the off-target inhibition of PDE11 might be reached.

Tadalafil treatment modifies the tumor microenvironment

To determine whether tadalafil treatment could modify the tumor microenvironment, immunofluorescence analyses were performed on the available paraffin-embedded tumor specimens evaluating CD69+CD8+ T cells, FoxP3+CD4+ T cells, and CD33+ IL4Rα+ MDSC concentrations. Particular attention was given to the FoxP3 intracellular localization because, as we previously demonstrated, the presence of CD4+ T cells with a cytoplasmatic FoxP3 expression correlates with a favorable prognosis, whereas an high concentration of CD4+ T cells expressing nuclear FoxP3 is strongly associated with recurrence (20). The comparison of tadalafil arms with the placebo group did not highlight any significant differences in either MDSCs or Tregs, although a higher variation is appreciable within the treatment groups and a trend (P = 0.09) toward a downregulation of MDSCs is detectable (Fig. 6A and B). Interestingly, a significant upregulation of CD69 is detectable within the CD8 T cells (Fig. 6C) with the 10-mg dose but not in the 20-mg study arm.

When the same analyses are conducted dividing patients according to the dose categories described above (Supplementary Fig. S3), a significant downregulation of both MDSCs and nFoxp3:cFoxp3 ratio becomes evident, whereas a trend toward increased CD8 activation is still appreciable at lower but not higher tadalafil doses (Supplementary Fig. S3C).

Discussion

The immune system plays a key role in the progression of HNSCC as initially suggested by the numerous immunologic defects and the expansion of immunosuppressive populations (i.e., MDSCs and Treg) both at the tumor site and in the blood (2). Therapeutic manipulation of the immune system and its response, by corollary, may play an equally significant role in the treatment of HNSCC. On the basis of our preclinical data (21, 22), we evaluated the immunomodulatory impact of a relatively short course of daily tadalafil administration in HNSCC with a proof-of-concept randomized, double-blind, placebo-controlled three-arm phase II clinical trial. Tadalafil was generally well tolerated (Supplementary Table S3) with adverse side effects prompting discontinuation of study drug (severe back pain or more generalized myalgia) arising in 10.3% (3 of 29) of tadalafil-treated patients. This number is consistent with what has been previously reported (36). All 3 patients had complete resolution of symptoms without sequelae within 24 hours after treatment interruption.

Because of the heterogeneity of MDSC phenotype across malignancies, we first defined the phenotype of MDSCs in the patients with HNSCC. Because some MDSC subsets (such as other myeloid populations) are poorly resistant to freezing and thawing, and considering the logistics of the clinical trial, we focused our attention on the cryoresistant MDSC population (mostly mMDSC) that can be easily recovered by Ficoll-Hypaque gradient.

Downloaded from clincancerres.aacrjournals.org on November 11, 2017. © 2015 American Association for Cancer Research.
It is important to note that the purification and cryopreservation procedures can alter the composition of the myeloid compartment. Nevertheless, differences induced by the pharmacologic treatment can still be determined by processing all samples in the same way and by using paired statistical analyses.

We determine for the first time in this human disease that the immunosuppressive activity within the CD33+ myeloid lineage is confined to the IL4Rα+ cells (Fig. 2A). These cells are characterized, as previously reported (7–11), as CD34+CD11b+CD14+HLADRint cells (Fig. 2B). The concentration of these cells within the tumor microenvironment correlates with the likelihood of oral SCC recurrence within 3 years (Fig. 2C), confirming an important role for MDSCs in tumor progression.

This trial confirms for the first time, in humans, the preclinical findings showing a beneficial immunomodulatory effect of PDE5 inhibition in the tumor bearer (21, 22, 37, 38): tadalafl significantly reduced MDSC and Treg numbers (Fig. 3) in the blood of patients with HNSCC while it increased the concentration of tumor-specific CD8+ T cells (Fig. 4). The reason for such a reduction of both MDSCs and Treg is still unknown. On the basis of our preclinical data, we can speculate that PDE5 inhibition can downregulate IL4Ra on MDSCs (21), reducing the survival signaling that this receptor mediates (26). Alternatively, it is possible that PDE5 blockade stops the positive loop by which MDSCs promote their own recruitment and differentiation (39).

The tadalafl-mediated reduction of circulating Treg does not seem to be related to a direct action of this drug because incubation of Treg with physiologically relevant concentrations of tadalafl does not increase their apoptosis in a small number of preliminary experiments performed (data not shown). Further study is needed to completely exclude this possibility. We have shown in a preclinical model that MDSCs can expand Treg in vivo and that PDE5 inhibition can block this process (22). Considering the rapid turnover of circulating Treg in the tumor-bearing host (40, 41), it is possible that MDSCs inhibition significantly decreases Treg proliferation without altering their elevated apoptotic rate, de facto reducing their frequency in the blood. Alternatively, the reduced Treg frequency in the blood and in the tumor after tadalafl treatment may be explained by altered Treg homing signaling due to changes in the tumor macroenvironment. Indeed, beneficial changes in the tumor macroenvironment are also suggested by the normalization of the CD4:CD8 T-cell ratio (Supplementary Table S5) and from the data of a similar but independent trial in which patients with HNSCC have been treated for 15 days with tadalafl before treatment (J. Califano and colleagues; submitted for publication). In that trial, it was shown that the fewer MDSCs present in the blood after tadalafl treatment were less suppressive and that
the immune response against the recall antigen Candida (as measured by delayed-type hypersensitivity) was significantly increased by tadalafil treatment compared with placebo. The increase of tumor-specific CD8\(^+\) T cells observed in the clinical trial described in this report can be a consequence of these changes in the tumor microenvironment that allows a spontaneous priming of the antitumor immune response.

Although the trial reported here was designed to compare two dosing groups of tadalafil (10 and 20 mg) with placebo, and no clear superiority of either group was identified, an analysis of the dose/response, expressed as \(\mu\)g/kg of drug, yielded surprising results: the most significant immunologic modification was achieved with an intermediate dose of tadalafil (between 145 and 225 \(\mu\)g/kg) equal to 10.15 to 17.57 mg/day for a 70-kg patient (Fig. 5A and B). We speculate that at higher dosage tadalafil can exert an off-target effect of inhibition of PDE11. Tadalafil, in fact, can inhibit both PDE5 and PDE11 with EC50 of 9.4 and 67 nmol/L, respectively (14), yielding a specificity of tadalafil for PDE5 7.1 times that of PDE11. This off-target inhibition may be relevant for tadalafil-mediated immunomodulatory properties because PDE11 can hydrolyze both cGMP and cAMP and because it is expressed in T cells and monocytes (42, 43). Increased cAMP levels can promote Treg proliferation (35), decrease CD8\(^+\) T-cell expansion (33), and prevent DC maturation (34), thus restring any immune activation. The inhibition of PDE11 may explain the unusual tadalafil dose–response curve: at high dosage (\(\geq 225 \mu\)g/kg/d), both cAMP and cGMP are upregulated in T cells, MDSCs, and APCs, whereas at the more effective intermediate dose, only cGMP is increased (Fig. 5C and D). Given that the trial design did not prospectively test these mg/kg dose categories, and given the small size of the trial, no firm conclusions can be stated regarding the optimal tadalafil dose strategy to use without further clinical testing of this interesting finding of a superior intermediate mg/kg dose category. Our data do add this possible negative immunomodulatory effect to the notes of caution already raised on the use of high daily doses of tadalafil because of its off-target inhibition of PDE11 thought to also be responsible for myalgic SAE and its negative impact on spermatogenesis (44).

Microscope-based immunofluorescence analysis of the tumor microenvironment seems to confirm the observed dose–response curve: (i) while a trend toward MDSC downregulation is observed in the study arms, a statistically significant reduction of both MDSCs and Tregs is seen when patients are subdivided into the identified dose categories (Supplementary Fig. S3); (ii) a significant upregulation of the activation marker CD69 is observed in the CD8\(^+\) T cells at lower but not at higher tadalafil doses. Although this trial has not measured survival or recurrence endpoints, it is important to emphasize that CD8\(^+\) T-cell activation at the tumor site has a positive prognostic value (45), whereas the accumulation of MDSCs (Fig. 1) and an increase in the nFoxp3:cFoxp3 ratio (20) has been correlated with tumor recurrence. Indeed, in our retrospective analysis, both MDSCs concentration and log2 (nFoxp3:cFoxp3) ratio at the tumor site maintained their significant predictivity for recurrence status in multivariate analysis with adjustment for clinical predictors (Supplementary Table S4). Tadalafil seems to beneficially modulate all these parameters, strongly supporting the necessity to perform a larger randomized trial with clinical endpoints to evaluate whether PDE5 inhibition should be incorporated with standard treatment of HNSCC or with other immunologic therapeutic interventions.

**Disclosure of Potential Conflicts of Interest**
P. Serafini and I. Borrello are inventors on a patent, which is owned by Johns Hopkins University, regarding the use of PDE5 inhibitors as immune-modulators. No potential conflicts of interest were disclosed by the other authors.

**Authors’ Contributions**
Conception and design: D.T. Weed, I. Reis, P. Serafini
Development of methodology: D.T. Weed, I. Reis, R. Nazarian, P. Serafini
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): D.T. Weed, J.L. Vella, A.C. De la fuente, C. Gomez, Z. Sargi, R. Nazarian, P. Serafini
Writing, review, and/or revision of the manuscript: D.T. Weed, J.L. Vella, I. Reis, Z. Sargi, J. Califano, I. Borrello, P. Serafini
Study supervision: D.T. Weed, P. Serafini

**Acknowledgments**
The authors thank Oliver Umland (DRI) for assistance with the cell-sorting, the imaging core at the DRI, the flow-cytometry core at the SCCC, Gail Walker for statistical help with the initial Trial design and interim analysis, and Mark Lippman for the critical reading of the article.

**Grant Support**
This work was entirely supported by the Flight Attendant Medical Research foundation YCSA award.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

References


38. Drennan S, Stafford ND, Greenman J, Green VL. Increased frequency and suppressive activity of CD127(−)CD25(−) regulatory T cells in the peripheral circulation of patients with head and neck squamous cell carcinoma are associated with advanced stage and nodal involvement. Immunology 2013;140:335–41.


Tadalafil Reduces Myeloid-Derived Suppressor Cells and Regulatory T Cells and Promotes Tumor Immunity in Patients with Head and Neck Squamous Cell Carcinoma

Donald T. Weed, Jennifer L. Vella, Isildinha M. Reis, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-14-1711

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2014/10/16/1078-0432.CCR-14-1711.DC1

Cited articles
This article cites 45 articles, 11 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/21/1/39.full#ref-list-1

Citing articles
This article has been cited by 7 HighWire-hosted articles. Access the articles at:
http://clincancerres.aacrjournals.org/content/21/1/39.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://clincancerres.aacrjournals.org/content/21/1/39.
Click on “Request Permissions” which will take you to the Copyright Clearance Center’s (CCC) Rightslink site.